Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | PNP | P00491 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.57 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.57 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.57 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.57 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311622 | 1.00 | HIF1A (0.58) | HIF1APNPLMNATP53HTT | |
| SCHEMBL3759135 | 0.87 | PNP (0.69) | HIF1APNPLMNATP53HTT | |
| SCHEMBL21625245 | 0.87 | PNP (0.69) | HIF1APNPLMNATP53HTT | |
| SCHEMBL3766539 | 0.87 | PNP (0.69) | HIF1APNPLMNATP53HTT | |
| SCHEMBL3766542 | 0.87 | PNP (0.69) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL5982293 | 0.84 | HIF1A (0.73) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL324457 | 0.84 | HIF1A (0.73) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL2000526 | 0.84 | HIF1A (0.73) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL24307 | 0.84 | HIF1A (0.73) | HIF1APNPLMNATP53HTT | |
| Deoxyinosine SCHEMBL7191121 | 0.84 | HIF1A (0.73) | HIF1APNPLMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 618 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630851-B2 | Polynucleotide modification methods | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-19 | — | — | US | claimed |
| US-12624387-B2 | Method for reducing primer dimer formation and increasing amplification efficiency | SEEGENE, INC. (KR) | 2026-05-12 | — | — | US | claimed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | claimed |
| US-12371736-B2 | TD probe and its uses | SEEGENE, INC. (KR) | 2025-07-29 | — | — | US | claimed |
| WO-2024136630-A1 | METHOD FOR SEQUENCE HOMOLOGY SEARCH OF NUCLEOTIDE DATABASE | 주식회사 씨젠 | 2024-06-27 | — | — | WO | claimed |
| EP-4293127-A2 | METHOD FOR REDUCING PRIMER DIMER FORMATION AND INCREASING AMPLIFICATION EFFICIENCY | Seegene, Inc. (KR) | 2023-12-20 | — | — | EP | claimed |
| EP-4001428-B1 | METHOD FOR REDUCING PRIMER DIMER FORMATION AND INCREASING AMPLIFICATION EFFICIENCY | SEEGENE INC (KR) | 2023-11-22 | — | — | EP | claimed |
| US-20230250474-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-10 | — | — | US | claimed |
| US-11542551-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-01-03 | — | — | US | claimed |
| CN-115341017-A | Kit and detection method for rapidly detecting gene variation based on lighted click connection probe | 中国人民解放军陆军特色医学中心 | 2022-11-15 | — | — | CN | claimed |
| WO-2006095941-A1 | PROCESSES USING DUAL SPECIFICITY OLIGONUCLEOTIDE AND DUAL SPECIFICITY OLIGONUCLEOTIDE | SEEGENE, INC. (KR) | 2006-09-14 | — | — | WO | claimed |
| WO-2005083121-A1 | METHOD FOR AMPLIFYING MEMBERS OF A GENE FAMILY | SEEGENE, INC. (KR) | 2005-09-09 | — | — | WO | claimed |
| WO-2005083120-A1 | METHOD FOR AMPLIFYING MEMBERS OF A GENE FAMILY | SEEGENE, INC. (KR) | 2005-09-09 | — | — | WO | claimed |
| US-20050164184-A1 | Hybridization portion control oligonucleotide and its uses | SEEGENE, INC. (KR) | 2005-07-28 | — | — | US | claimed |
| WO-2005045073-A1 | METHOD FOR AMPLIFYING UNKNOWN DNA SEQUENCE ADJACENT TO KNOWN SEQUENCE | SEEGENE, INC. (KR) | 2005-05-19 | — | — | WO | claimed |
| EP-1448795-A1 | HYBRIDIZATION PORTION CONTROL OLIGONUCLEOTIDE AND ITS USES | Seegene, Inc. (KR) | 2004-08-25 | — | — | EP | claimed |
| EP-1448793-A1 | ANNEALING CONTROL PRIMER AND ITS USES | Seegene, Inc. (KR) | 2004-08-25 | — | — | EP | claimed |
| US-20030175749-A1 | Annealing control primer and its uses | SEEGENE, INC. (KR) | 2003-09-18 | — | — | US | claimed |
| WO-2003050306-A1 | HYBRIDIZATION PORTION CONTROL OLIGONUCLEOTIDE AND ITS USES | SEEGENE, INC. (KR) | 2003-06-19 | — | — | WO | claimed |
| WO-2003050305-A1 | ANNEALING CONTROL PRIMER AND ITS USES | SEEGENE, INC. (KR) | 2003-06-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | HIF1A 3888/4885PNP 8/4885LMNA 171/4885 |
| US-12630851-B2 | Polynucleotide modification methods | PNP, NT5C3B, UNG | HIF1A 2561/4885PNP 1/4885LMNA 1393/4885 |
| US-12624387-B2 | Method for reducing primer dimer formation and increasing amplification efficiency | UBR4, UBAP2, UBAP2L | HIF1A 2852/4885PNP 1201/4885LMNA 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.